Patent · US Expired

Vaccinia virus MVA-E3L-knockout-mutants and use thereof

US7049145B2 · kind B2 · utility

19Cited by

3References

23Claims

0Family size

Assignee

GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH · DE

Inventors

Volker Erfle · Munich, DE
Simone Hornemann · Birkenfeld, DE
Gerd Sutter · Munich, DE

Key dates

Filing date	Sep 11, 2002
Grant date	May 23, 2006
Priority date	—
Expiry date	Sep 11, 2022

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.